|Aegis Capital Corp.|
|810 Seventh Avenue, 18 th Floor|
|New York, New York 10019|
TheStreet's biotech columnist offers his own report card on biotech stocks.
CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.